biostudies-literatureAfentou NNational Institute for Health Research (NIHR)605-617https://www.ebi.ac.uk/biostudies/studies/S-EPMC9283622biostudies-literatureUnknown6(4)<h4>Background</h4>Childhood steroid-sensitive nephrotic syndrome is a frequently relapsing disease with significant short- and long-term complications, leading to high healthcare costs and reduced quality of life for patients. The majority of relapses are triggered by upper respiratory tract infections (URTIs) and evidence shows that daily low-dose prednisolone at the time of infection may reduce the risk of relapse.<h4>Objective</h4>The aim of this study was to assess the cost effectiveness of a 6-day course of low-dose prednisolone at the start of a URTI when compared with placebo.<h4>Methods</h4>A state-transition Markov model was developed to conduct a cost-utility analysis with the outcome measured in quality-adjusted life-years (QALYs). Resource use and outcome data were derived froPharmacoEconomics - openEconomic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis.PMC928362211/129/261Allison KSandhu SCrulley Team SGribbin AMagadevan TWest NFenton TPlaatjies NHenry Team JCockerill HSamm KMurray Team MAyub NMcKeever KWright DDatta VCoke Team LMoulds CCollier HMaxwell HBeer NSwingler RBoswell SAfentou NLancaster Team ABowker ROxley CHothi DLancoma-Malcolm IBolger ABrettell EButterworth SD'Costa SAye MOates BHallett Team SSharman SJSmith Team SRoe Team ECastle Team GMathew VRoper AWhincup GNavarra HTurner AJones GHolt RLakshman RFear LJones CRhodes SShenoy MKelly AShrivastava AScanlan JMoya EHaskell LJadresic LParikh AHall AYadav PPhipps MGupta RDuncan KTeam WWebb DAslam MLogie IMGupta VSuri SGreen DYendle Team LPetkar AYussuf SVincent OFinlay EWebb NPlant NSolebo JKaviethasan STandle VBackhouse Team CWhite Team SThorne Team NWebb AKaur ADe-Beger SKaur DBolger Team AKhan Team NHarms BVella ECoad NPREDNOS Collaborative Group, NIHR Medicines for Children Research Network Nephrology Clinical Studies GroupThin Saing THarrill CEgginton DShackleton JTse YHaq SPhilps Team JConnon Team MSharma AChristian MTClough Team SCottis HHunt CGilbert RMehta SGoodyear PMoakes CReynolds BGupta MNair Catherine Tarn Nozedar AO'Connor GChristian MAbou-Rayyah Team MIqbal JElhadi NHowell JMsiska MParker HDawson TFrew EHegde SBibi Team FShortland SParker ASood RNichols Team JBennett Team SWallace DWoolley RBuck JWinkles NMukhopadhyay SWilkins Team SMuller JMorrison ZWoodhead TeamMadalitso Kubwalo LCansick JBurchett CBlackburn HWardrop Team JJohnson SBilolikar Hvon Bremen BEtuwewe BCesar KEgginton Team DHolliday CAyonrinde ONewnham ABroodbank DWellings Team LCarswell HHulse Team WKoziell ATheresa Moorcroft LOBell CMalina MBrettell EABell KRoff Team ASaleem MCollins EVemuri GTemlett EHuma ZReid CUpton CCrosbie EKilroy Team SShah DBazaya TRaja SHadebe BBockenhauer DAhmed MRowlands Stephanie Chamberlain CO'Brien KWright Team FLosa IHughes DBingham Team VWobi BCraze JEisenhut MNorton IMilford DVHesseling MBeames SDarwood IKrishnan RIbrahim ZWadams SHall ASElizabethSambo ADavies KPhipps Team MDyer SWoolley RLBurnett Team CCook WShakeshaft Team JCowley ADalton DFairhead LJaved MNardeosingh NPThomas MSukthankar SBooth JHunt Team LKempson SWheeler MDeakin KNatesan KTyerman KLunn AKelsall NIves NGalinha CBalasubramanian KBeeby DHillman KBrearey SWoodhead LSamuel RConway SLinton CAllen MDavison ABodenham-Chilton HPrajapati HBrown AWalding Team LThattakkat KIves NJElliott KGadong NOnifade ELambert HThompson Team DSinha MCuthell OBarratt AWatson FWatson APemberton Team NEdees SMagier CWebb NJAAkhtar NSingh RBentsi-Enchill EWeston ABrennan NHobson Team LLeitch Team KMusselwhite JDekker SCarey JAnguvaa LMillar Team MFurness Team RKeenan Team NBhatti TFormosa MSaleem MABasharat FMcGregor TJayachandran DShackleton Team JRajkowski TPower SBarsoum EKhoobarry KAnjum BMahadevan-Bava SRamsay MAhmad Team MSayan Team ADe Jesus Team HMcCready SRfidah ETomlinson JButler Team SPadmakumar BMillman GSathyanarayan VCope SBranson AKhan ARBaggott JVenkatesh URogers NMoon Team AJoshi VLanglands JDiskin LMorgan HSmith DGilbert RDSmith CDerry CMuogbo DClayton ASmith AHarmer MSmith HKhan AMatos Team NWaxman Team EMeyrick SCampbell JHolbrook Team BHove OGreen Team JDate ACampbell CCooper COwen Team CYu LMGordon ALall RfalseEconomic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis.<h4>Background</h4>Childhood steroid-sensitive nephrotic syndrome is a frequently relapsing disease with significant short- and long-term complications, leading to high healthcare costs and reduced quality of life for patients. The majority of relapses are triggered by upper respiratory tract infections (URTIs) and evidence shows that daily low-dose prednisolone at the time of infection may reduce the risk of relapse.<h4>Objective</h4>The aim of this study was to assess the cost effectiveness of a 6-day course of low-dose prednisolone at the start of a URTI when compared with placebo.<h4>Methods</h4>A state-transition Markov model was developed to conduct a cost-utility analysis with the outcome measured in quality-adjusted life-years (QALYs). Resource use and outcome data were derived fro2022-01-01T00:00:00Z2022 Jul2026-05-09T12:32:52.058Z2022-07-19T08:19:18.459ZS-EPMC92836223573307610.1007/s41669-022-00334-6